Sunday 18 October 2026
Export ARTV’s income statement to Excel — free account
Artiva Biotherapeutics, Inc.
ARTV Healthcare Biotechnology
Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.85
0.21
−3.47%
Follow ARTV
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — |
Altman Z-Score |
— | 1.27 | — |
P/S ratio |
0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(4.00) | 8.07 | — |
P/Operating CF |
(0.71) | (7.75) | — |
Beneish M-Score |
— | (22.63) | — |
P/B ratio |
0.00 | 0.61 | — |
Price to Tangible BV |
0.00 | 0.61 | — |
EV/Sales |
0.00 | 0.00 | — |
EV/EBITDA |
1.23 | 1.11 | — |
EV/Operating CF |
0.73 | 1.31 | — |
EV/FCF |
0.71 | 1.29 | — |
Quick Ratio |
6.44 | 15.15 | 8.26 |
Current Ratio |
6.53 | 15.39 | 8.61 |
Net Debt/EBITDA |
2.71 | 2.86 | 1.24 |
Debt/Assets |
0.00% | 0.02% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.65 | 0.84 | 0.92 |
Capex/Depreciation |
(1.44) | (0.26) | (1.00) |
| 0.00% | (530.93%) | (56.55%) | |
| 0.00% | (41.55%) | (49.26%) | |
ROIC |
0.00% | (3,345.37%) | (2,860.92%) |
Return on Tangible Assets |
(37.94%) | (35.77%) | (78.97%) |
Average Days of Receivables |
19.16 | 212.31 | 0.00 |
Research and Development Expense of Revenue |
150.04% | 20,051.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
41.54% | 6,854.58% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21.06% | 2,780.88% | 0.00% |
Graham Net Nets |
(22.32) | 1.46 | — |
Graham Number |
0.00 | 0.00 | — |
Earnings Yield |
(327.93%) | (57.60%) | — |
Free Cash Flow Yield |
(528.96%) | (49.06%) | — |
Revenue per Share |
41.72 | 0.02 | 0.00 |
Operating CF per Share |
(59.09) | (4.89) | (3.14) |
Capex per Share |
(4.06) | (0.06) | (0.11) |
Free Cash Flow per Share |
(63.15) | (4.94) | (3.25) |
Cash per Share |
95.89 | 16.47 | 4.42 |
Shareholders Equity per Share |
(201.84) | 16.58 | 4.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(201.84) | 16.58 | 4.50 |
Free Cash Flow |
(50.69) | (55.67) | (79.34) |
Working Capital |
67.59 | 176.38 | 99.58 |
Capital Expenditures |
(3.26) | (0.64) | (2.59) |
Net Current Asset Value |
(187.31) | 165.69 | 91.70 |
EV/EBIT |
1.16 | 1.07 | — |
Capex to Sales |
0.10 | 2.56 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — |
| Other line items | |||
Depreciation/Fixed assets |
0.28 | 0.38 | 0.39 |
Cash ROIC |
59.60% | (14.96%) | (36.40%) |
Accounts Receivable Turnover |
0.00 | 0.26 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.95 | 0.11 |
Average Payables |
— | 0.87 | 0.74 |
Average Assets |
— | 157.35 | 170.26 |
Average Common Equity |
— | 12.31 | 148.31 |
Columns are period end dates